Abstract
Purpose: We aimed to assess whether the aberrant methylation of GNAQ gene, which may involve in the clopidogrel resistance (CR), was associated with a higher risk of recurrent ischemic events in clopidogrel-treated acute ischemic stroke or transient ischemic attack (TIA) patients. Methods: This is a nested case-control study, 152 clopidogrel-treated acute ischemic stroke or TIA patients that were propensity-matched were included in the final analysis, including 36 patients with vascular recurrence set as cases. Methylation levels of GNAQ gene were identified with MassARRAY EpiTYPER assays. Univariate and multivariate logistic regression analyses were conducted to explore the predictive value of CpG units for recurrent ischemic events within 1 year.Mediation analysis was performed to assess the role of CR in describing the effect of GNAQ methylation on recurrent ischemic events. Results: A total of 16 differentially methylated CpG units were identified. Multivariate logistic analysis indicated that the average methylation of CpG 32–39 of GNAQ was associated with a significantly higher risk of ischemic events (p < 0.001). When transformed into dichotomous variables with the receiver operating characteristic curve, hypomethylation (<0.31) of CpG 32–39 of GNAQ significantly increased the risk of vascular recurrence (odds ratio 73.82, 95% confidence interval 20.33–268.01). The mediation effect of CR for recurrent ischemic events was not identified. Conclusions: Hypomethylation of CpG 32–39 of GANQ gene was associated with a higher risk of ischemic events for clopidogrel-treated acute ischemic stroke or TIA patients. Further studies were warranted to explain the possible mechanism.
References
1.
Luengo-Fernandez
R
, Gray
AM
, Rothwell
PM
. Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison
. Lancet Neurol
. 2009
;8
(3
):235
–43
. .2.
Bevan
S
, Traylor
M
, Adib-Samii
P
, Malik
R
, Paul
NL
, Jackson
C
, Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations
. Stroke
. 2012
;43
(12
):3161
–7
.3.
CAPRIE Steering Committee
. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
. Lancet
. 1996
;348
(9038
):1329
–39
. .4.
Rothwell
PM
, Algra
A
, Chen
Z
, Diener
HC
, Norrving
B
, Mehta
Z
. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials
. Lancet
. 2016
;388
(10042
):365
–75
. .5.
Wang
Y
, Wang
Y
, Zhao
X
, Liu
L
, Wang
D
, Wang
C
, Clopidogrel with aspirin in acute minor stroke or transient ischemic attack
. N Engl J Med
. 2013
;369
(1
):11
–9
.6.
Johnston
SC
, Easton
JD
, Farrant
M
, Barsan
W
, Conwit
RA
, Elm
JJ
, Clopidogrel and Aspirin in acute ischemic stroke and high-risk TIA
. N Engl J Med
. 2018
;379
(3
):215
–25
.7.
Sussman
ES
, Jin
M
, Pendharkar
AV
, Pulli
B
, Feng
A
, Heit
JJ
, Dual antiplatelet therapy after carotid artery stenting: trends and outcomes in a large national database
. J Neurointerv Surg
. 2021
;13
(1
):8
–13
.8.
Angiolillo
DJ
, Fernandez-Ortiz
A
, Bernardo
E
, Alfonso
F
, Macaya
C
, Bass
TA
, Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives
. J Am Coll Cardiol
. 2007
;49
(14
):1505
–16
.9.
Moosavi
A
, Motevalizadeh Ardekani
A
. Role of epigenetics in biology and human diseases
. Iran Biomed J
. 2016
;20
(5
):246
–58
. .10.
Wierda
RJ
, Geutskens
SB
, Jukema
JW
, Quax
PH
, van den Elsen
PJ
. Epigenetics in atherosclerosis and inflammation
. J Cell Mol Med
. 2010
;14
(6A
):1225
–40
. .11.
Gallego-Fabrega
C
, Carrera
C
, Reny
JL
, Fontana
P
, Slowik
A
, Pera
J
, TRAF3 epigenetic regulation is associated with vascular recurrence in patients with ischemic stroke
. Stroke
. 2016
;47
(5
):1180
–6
.12.
Su
J
, Li
J
, Yu
Q
, Xu
X
, Wang
J
, Yang
J
, Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease
. J Clin Lab Anal
. 2019
;33
(5
):e22867
.13.
Su
J
, Zheng
N
, Li
Z
, Huangfu
N
, Mei
L
, Xu
X
, Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients
. J Clin Lab Anal
. 2020
;34
(2
):e23040
.14.
Su
J
, Yu
Q
, Zhu
H
, Li
X
, Cui
H
, Du
W
, The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population
. PLoS One
. 2017
;12
(3
):e0174511
.15.
Su
J
, Li
X
, Yu
Q
, Liu
Y
, Wang
Y
, Song
H
, Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients
. Biomed Res Int
. 2014
;2014
:450814
.16.
Wang
L
, Ostberg
O
, Wihlborg
AK
, Brogren
H
, Jern
S
, Erlinge
D
. Quantification of ADP and ATP receptor expression in human platelets
. J Thromb Haemost
. 2003
;1
(2
):330
–6
. .17.
Kunapuli
SP
, Dorsam
RT
, Kim
S
, Quinton
TM
. Platelet purinergic receptors
. Curr Opin Pharmacol
. 2003
;3
(2
):175
–80
. .18.
Gao
S
, Wang
YJ
, Xu
AD
, Li
YS
, Wang
DZ
. Chinese ischemic stroke subclassification
. Front Neurol
. 2011
;2
:6
. .19.
Fukuoka
T
, Furuya
D
, Takeda
H
, Dembo
T
, Nagoya
H
, Kato
Y
, Evaluation of clopidogrel resistance in ischemic stroke patients
. Intern Med
. 2011
;50
(1
):31
–5
.20.
Fong
J
, Cheng-Ching
E
, Hussain
MS
, Katzan
I
, Gupta
R
. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke
. J Stroke Cerebrovasc Dis
. 2011
;20
(3
):227
–30
. .21.
Felsenfeld
G
. A brief history of epigenetics
. Cold Spring Harb Perspect Biol
. 2014
;6
(1
):a018200
. .22.
Wilson
AS
, Power
BE
, Molloy
PL
. DNA hypomethylation and human diseases
. Biochim Biophys Acta
. 2007
;1775
(1
):138
–62
. .23.
Feinberg
AP
, Koldobskiy
MA
, Göndör
A
. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
. Nat Rev Genet
. 2016
;17
(5
):284
–99
. .24.
Ehrlich
M
. DNA hypermethylation in disease: mechanisms and clinical relevance
. Epigenetics
. 2019
;14
(12
):1141
–63
. .25.
Yang
J
, Yu
Q
, Xu
Z
, Zheng
N
, Zhong
J
, Li
J
, Clopidogrel resistance is associated with DNA methylation of genes from whole blood of humans
. Front Genet
. 2020
;11
:583215
.26.
Sukmawan
R
, Hoetama
E
, Suridanda Danny
S
, Giantini
A
, Listiyaningsih
E
, Gilang Rejeki
V
, Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)
. Pharmacol Res Perspect
. 2021
;9
(2
):e00738
.27.
Leon
C
, Hechler
B
, Freund
M
, Eckly
A
, Vial
C
, Ohlmann
P
, Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice
. J Clin Invest
. 1999
;104
(12
):1731
–7
.28.
Baurand
A
, Raboisson
P
, Freund
M
, Léon
C
, Cazenave
JP
, Bourguignon
JJ
, Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist
. Eur J Pharmacol
. 2001
;412
(3
):213
–21
.29.
Ohlmann
P
, Eckly
A
, Freund
M
, Cazenave
JP
, Offermanns
S
, Gachet
C
. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq
. Blood
. 2000
;96
(6
):2134
–9
. .30.
Eckly
A
, Gendrault
JL
, Hechler
B
, Cazenave
JP
, Gachet
C
. Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation
. Thromb Haemost
. 2001
;85
(4
):694
–701
. .31.
Fabre
JE
, Nguyen
M
, Latour
A
, Keifer
JA
, Audoly
LP
, Coffman
TM
, Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice
. Nat Med
. 1999
;5
(10
):1199
–202
.32.
Hardy
AR
, Jones
ML
, Mundell
SJ
, Poole
AW
. Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets
. Blood
. 2004
;104
(6
):1745
–52
. .33.
Kuijpers
MJE
, Mattheij
NJA
, Cipolla
L
, van Geffen
JP
, Lawrence
T
, Donners
MMPC
, Platelet CD40L modulates thrombus growth via phosphatidylinositol 3-kinase β, and not via CD40 and IκB kinase α
. Arterioscler Thromb Vasc Biol
. 2015
;35
(6
):1374
–81
. .34.
Gallego-Fabrega
C
, Carrera
C
, Reny
JL
, Fontana
P
, Slowik
A
, Pera
J
, PPM1A methylation is associated with vascular recurrence in aspirin-treated patients
. Stroke
. 2016
;47
(7
):1926
–9
.35.
Samarakoon
R
, Chitnis
SS
, Higgins
SP
, Higgins
CE
, Krepinsky
JC
, Higgins
PJ
. Redox-induced Src kinase and caveolin-1 signaling in TGF-β1-initiated SMAD2/3 activation and PAI-1 expression
. PLoS One
. 2011
;6
(7
):e22896
. .36.
Zaina
S
, Heyn
H
, Carmona
FJ
, Varol
N
, Sayols
S
, Condom
E
, DNA methylation map of human atherosclerosis
. Circ Cardiovasc Genet
. 2014
;7
(5
):692
–700
.37.
Valencia-Morales Mdel
P
, Zaina
S
, Heyn
H
, Carmona
FJ
, Varol
N
, Sayols
S
, The DNA methylation drift of the atherosclerotic aorta increases with lesion progression
. BMC Med Genomics
. 2015
;8
:7
.38.
Smolarek
I
, Wyszko
E
, Barciszewska
AM
, Nowak
S
, Gawronska
I
, Jablecka
A
, Global DNA methylation changes in blood of patients with essential hypertension
. Med Sci Monit
. 2010
;16
(3
):CR149
–155
.39.
Bogdarina
I
, Welham
S
, King
PJ
, Burns
SP
, Clark
AJ
. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension
. Circ Res
. 2007
;100
(4
):520
–6
. .40.
Goyal
R
, Goyal
D
, Leitzke
A
, Gheorghe
CP
, Longo
LD
. Brain renin-angiotensin system: fetal epigenetic programming by maternal protein restriction during pregnancy
. Reprod Sci
. 2010
;17
(3
):227
–38
. .41.
Liu
R
, Jin
Y
, Tang
WH
, Qin
L
, Zhang
X
, Tellides
G
, Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity
. Circulation
. 2013
;128
(18
):2047
–57
.42.
Cattaneo
M
. Diagnosis and management of high platelet reactivity on treatment with clopidogrel
. Semin Thromb Hemost
. 2012
;38
(7
):645
–51
. .43.
Larsen
PD
, Holley
AS
, Sasse
A
, Al-Sinan
A
, Fairley
S
, Harding
SA
. Comparison of multiplate and verifyNow platelet function tests in predicting clinical outcome in patients with acute coronary syndromes
. Thromb Res
. 2017
;152
:14
–9
. .44.
Valenti
R
, Marcucci
R
, Capodanno
D
, De Luca
G
, Migliorini
A
, Gori
AM
, Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study
. J Thromb Thrombolysis
. 2015
;40
(1
):76
–82
. .45.
Rao
Z
, Zheng
H
, Wang
F
, Wang
A
, Liu
L
, Dong
K
, The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA
. Neurol Res
. 2017
;39
(8
):719
–26
.46.
Buonamici
P
, Marcucci
R
, Migliorini
A
, Gensini
GF
, Santini
A
, Paniccia
R
, Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
. J Am Coll Cardiol
. 2007
;49
(24
):2312
–7
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
